1. Cannabidiolic acid (CBDA) inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA; it offers potential therapeutic modality in the abrogation of cancer cell migration, including aggressive breast cancers.
2. Cannabidiolic acid displays significantly greater potency at inhibiting vomiting in shrews and nausea in rats, and at enhancing 5-HT(1A) receptor activation, an action that accounts for its ability to attenuate conditioned gaping in rats.
3. Cannabidiolic acid selectively inhibits cyclooxygenase (COX)-2 activity with an IC(50) value around 2 microM, has 9-fold higher selectivity than COX-1 inhibition.
4. Cannabidiolic acid and cannabidiol have inhibitory actions on the intestines of S. murinus that are not neuronallymediated or mediated via CB1 or CB2 receptors.
1. Pachypodol has cytotoxic potential ,can inhibit the growth of CaCo 2 colon cancer cell line in vitro.
2. Pachypodol has antibacterial and antifungal activities against Bacillus subtilis, Staphylococcus aureus, Staphylococcus faecalis, Echerichia coli, Pseudomonas aeruginosa, Candida albicans, Candida krusei and Candida galabrata.
3. Pachypodol exhibits anti-emetic effects.
4. Pachypodol inhibits the water-splitting enzyme activity.
Palonosetron hydrochloride is the only serotonin receptor antagonist approved for prevention of delayed chemotherapy-induced nausea and vomiting (CINV) caused by moderate emetogenic chemotherapy (MEC).